MeiraGTx Reports First Quarter 2020 Financial Results

May 07, 2020

LONDON and NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on recent progress.

During the first quarter of 2020, MeiraGTx remained focused on achieving its most important priorities for patients, including advancing its inherited retinal disease programs, progressing its xerostomia program through ongoing clinical studies, preparing for the next clinical trial of AAV-GAD for Parkinson’s disease and planning the buildout of its second viral vector and plasmid manufacturing facility. In response to the COVID-19 pandemic, the Company is working closely with its development partners and clinical sites to implement solutions enabling continuity of study conduct while protecting the health and safety of employees, patients and healthcare providers.

“Our teams in the UK, U.S. and Netherlands are working tirelessly to minimize the disruption caused by the global COVID-19 pandemic and continue our mission of improving the lives of people with serious diseases,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “Thank you to the MeiraGTx team and our collaborators for their dedication and commitment to developing transformative medicines during this challenging time.”

As of March 31, 2020, MeiraGTx had cash, cash equivalents and restricted cash of approximately $211 million. The Company believes this capital will be sufficient to fund operating expenses and capital expenditure requirements into 2022.

Inherited Retinal Disease (IRD) Portfolio:

  • MeiraGTx remains on track to report data from the ongoing Phase 1/2 clinical trial of AAV-RPGR for the treatment of X-linked retinitis pigmentosa in 2020, and continues to engage with global regulatory authorities as anticipated to advance the Company’s IRD programs.

AAV-AQP1 for the treatment of Grade 2/3 Radiation-Induced Xerostomia:  

  • Patients who have been treated in MeiraGTx’s Phase 1/2 AQUAx trial are continuing post-treatment follow-up assessments. The Company anticipates that treatment of new patients will resume in the second quarter of 2020. MeiraGTx expects to report preliminary clinical data from this trial in the second half of 2020.

AAV-GAD for the treatment of Parkinson’s Disease:

  • MeiraGTx has initiated the process for cGMP-grade AAV-GAD material and expects to file an Investigational New Drug (IND) application in late 2020 or early 2021.

Manufacturing and Supply Chain:

  • MeiraGTx continues to anticipate that its cGMP plasmid production facility will be operational by the end of 2020, and that its second cGMP viral vector manufacturing facility will be operational in 2021.
  • The Company has not experienced COVID-19 related supply chain disruptions and does not anticipate encountering supply chain disruptions that will impact its ability to support its current manufacturing and clinical trial activities.             

For more information related to our clinical trials, please visit

Financial Results
Cash, cash equivalents and restricted cash were $210.8 million as of March 31, 2020, compared to $227.4 million as of March 31, 2019.

License revenue was $4.2 million for the quarter ended March 31, 2020, compared to $0.8 million for the quarter ended March 31, 2019. The increase represents increased amortization of the $100.0 million upfront payment that the Company received in March 2019 from its collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Research and development expenses were $8.1 million for the quarter ended March 31, 2020, compared to $13.0 million for the quarter ended March 31, 2019. The decrease of $4.9 million was primarily due to an increase in research funding under the Janssen collaboration agreement in the amount of $12.7 million, which was partially offset by increases in costs related to the manufacture of material for clinical trials and costs related to clinical trials.

General and administrative expenses were $11.8 million for the quarter ended March 31, 2020, compared to $8.5 million for the quarter ended March 31, 2019. The increase of $3.3 million was primarily due to increases in share-based compensation, payroll and payroll related costs, insurance costs and rent and facilities costs, which was partially offset by a decrease in legal and consulting fees.

Foreign currency loss was $0.8 million for the quarter ended March 31, 2020, compared to a gain of $2.7 million for the quarter ended March 31, 2019. The decrease of $3.5 million was primarily due to a strengthening of the U.S. dollar against the pound sterling during the quarter ended March 31, 2020.

Net loss attributable to ordinary shareholders for the quarter ended March 31, 2020 was $15.7 million, or $0.43 basic and diluted net loss per ordinary share, compared to a net loss attributable to ordinary shareholders of $18.0 million, or $0.62 basic and diluted net loss per ordinary share for the quarter ended March 31, 2019.  

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit

Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our product candidate development and anticipated 2020 milestones regarding our pre-clinical and clinical data and reporting of such data and the timing of results of data, including in light of the COVID-19 pandemic, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, acquire additional capital, identify additional and develop existing product candidates, successfully execute strategic priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; the impact of the COVID-19 pandemic on the status, enrollment, timing and results of our clinical trials and on our business, results of operations and financial condition; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials or other manufacturing issues; changes in healthcare laws; risks associated with our international operations; significant competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; changes in tax policy or treatment; our ability to utilize our loss and tax credit carryforwards; litigation risks; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.


Elizabeth Broder
(646) 860-7983


W2O pure
Christiana Pascale
(212) 267-6722

    March 31   December 31
    2020   2019 
CURRENT ASSETS:            
Cash and cash equivalents   $  210,409,650     $  227,233,384  
Restricted cash      377,598        —  
Accounts receivable - related party      27,979,259        23,337,377  
Prepaid expenses      3,460,056        4,464,085  
Tax incentive receivable      6,819,851        11,974,437  
Other current assets      1,965,752        1,970,585  
Total Current Assets      251,012,166        268,979,868  
Property and equipment, net      25,430,812        23,858,108  
Security deposits      709,886        951,138  
In-process research and development      762,285        777,655  
Restricted cash      —        123,376  
Other assets      191,198        195,053  
Right-of-use assets      26,561,496        29,002,448  
TOTAL ASSETS   $  304,667,843     $  323,887,646  
Accounts payable   $  7,288,347     $  3,759,339  
Accrued expenses      12,784,394        18,083,757  
Lease obligations, current      1,962,363        1,674,210  
Deferred revenue - related party, current      20,930,133        25,678,515  
Other current liabilities      60,780        —  
Total Current Liabilities      43,026,017        49,195,821  
Deferred revenue - related party      55,700,543        60,535,576  
Lease obligations      19,172,729        21,504,340  
Asset retirement obligations      1,652,570        1,654,755  
Deferred income tax liability      191,198        195,053  
TOTAL LIABILITIES      119,743,057        133,085,545  
Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized, 36,817,916 and 36,791,906 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively      1,430        1,429  
Capital in excess of par value      401,488,623        395,630,666  
Accumulated other comprehensive income (loss)      2,151,882        (1,794,042 )
Accumulated deficit      (218,717,149 )      (203,035,952 )
Total Shareholders' Equity      184,924,786        190,802,101  
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY   $  304,667,843     $  323,887,646  

    For the Three Months Ended March 31
    2020     2019
License revenue - related party   $  4,209,576     $  784,960  
Operating expenses:            
General and administrative      11,806,134        8,499,475  
Research and development      8,083,342        12,976,229  
Total operating expenses      19,889,476        21,475,704  
Loss from operations      (15,679,900 )      (20,690,744 )
Other non-operating income (expense):            
Foreign currency (loss) gain      (756,701 )      2,718,400  
Interest income      789,370        —  
Interest expense      (33,966 )      (9,574 )
Net loss      (15,681,197 )      (17,981,918 )
Other comprehensive income (loss):            
Foreign currency translation gain (loss)      3,945,924        (1,133,683 )
Total comprehensive loss   $  (11,735,273 )   $  (19,115,601 )
Basic and diluted net loss per ordinary share   $  (0.43 )   $  (0.62 )
Weighted-average number of ordinary shares outstanding      36,624,950        28,776,915  

MGX logo.png

Source: MeiraGTx